Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.

[1]  A. Chen,et al.  Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083 , 2017, Clinical Cancer Research.

[2]  R. Plummer,et al.  A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours , 2017, British Journal of Cancer.

[3]  V. Giranda,et al.  A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC) , 2015, Cancer Chemotherapy and Pharmacology.

[4]  Liang Zhao,et al.  FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy , 2015, Clinical Cancer Research.

[5]  T. Owonikoko,et al.  A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511). , 2015, Lung cancer.

[6]  D. Santini,et al.  BRCA-Associated Ovarian Cancer: From Molecular Genetics to Risk Management , 2014, BioMed research international.

[7]  A. Chen,et al.  Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt). , 2014 .

[8]  S. D. de Morais,et al.  Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K). , 2013, Journal of pharmaceutical sciences.

[9]  A. Toss,et al.  Molecular Mechanisms of PARP Inhibitors in BRCA-related Ovarian Cancer , 2013 .

[10]  Sheena M. Scroggins,et al.  Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas , 2013, Clinical Cancer Research.

[11]  J. Yi,et al.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Kaufmann,et al.  PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.

[13]  A. Montagnoli,et al.  Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity? , 2009, Expert opinion on therapeutic patents.

[14]  Larry Rubinstein,et al.  Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Jian Wang,et al.  Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. , 2007, Journal of the National Cancer Institute.

[16]  E. Eisenhauer,et al.  Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Rose.  Gemcitabine reverses platinum resistance in platinum‐resistant ovarian and peritoneal carcinoma , 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[18]  G. de Murcia,et al.  The PARP superfamily , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[19]  V. Torri,et al.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial , 2003, The Lancet.

[20]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Noda,et al.  Enhanced polyadenosine diphosphate‐ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma , 2001, Journal of gastroenterology and hepatology.

[22]  B. Carlin,et al.  Adaptive design improvements in the continual reassessment method for phase I studies. , 1999, Statistics in medicine.

[23]  T. Taniguchi,et al.  Enhanced expression of poly(ADP‐ribose) synthetase gene in malignant lymphoma , 1991, American journal of hematology.

[24]  O. Hayaishi,et al.  Aberration of poly(adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers. , 1983, Cancer research.

[25]  M. Garbrecht,et al.  ADP-ribosylation of nuclear proteins in normal lymphocytes and in low-grade malignant non-Hodgkin lymphoma cells. , 1980, European journal of biochemistry.

[26]  H. Mackay,et al.  Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. , 2015, The Lancet. Oncology.